SAMSUNG-ELECTRONICS-CO.
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today unveiled an expanded portfolio of cutting-edge foundry solutions at its Samsung Foundry Forum (SFF) 2019 Munich.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005312/en/
Samsung attracted more than 200 industry experts from fabless companies and foundry partners, and 16 partner booths displayed advanced foundry technology trends, a significant increase in both numbers compared to last year, representing a more solid customer base of Samsung Foundry as well as greater collaboration in Europe, Middle East, and Africa (EMEA).
Since the EMEA semiconductor market is in demand across a wide range of applications including automotive, consumer, network, and internet-of things (IoT), Samsung introduced various specialty technologies, such as FD-SOI, radio frequency (RF), and embedded memory along with comprehensive portfolio of foundry process nodes.
Samsung Electronics showcased its state-of-the-art foundry platforms that bring together essential technical elements for new-age applications, including 5G, IoT, automotive, and high performance computing (HPC), while expanding its design solution partners to improve global customers' access to Samsung's foundry solutions.
"It is a great honor to host our global foundry forum with increasing number of attendees every year. The forum has helped us work closely with our customers and strengthen Samsung's foundry ecosystem," said Dr. ES Jung, president and head of foundry business at Samsung Electronics, in the keynote speech. "We will strive to get more customer' trust and be the best partner possible to prepare for the future with."
Given the robustness of the European automotive industry, the foundry platform for automotive semiconductor market is drawing considerable attention, and is expected to rapidly grow to address the increasing demand in the autonomous and electric vehicle market.
Samsung is currently producing several automotive semiconductor products such as driving assistant and infotainment systems, mainly based on its 28-nanometer (nm) FD-SOI and 14nm process nodes. In order to respond to increasing customer inquiries, Samsung plans to expand its automotive process nodes to 8nm in near future.
Samsung is also focusing on functional safety and component reliability, which are critically important in the automotive industry, since any failure could cause serious consequences of accident or injury.
Samsung has already proven its ability to design IPs to meet the required automotive standard, and received the ISO 26262 certification for functional safety in automotive components from TÜV Rheinland. Complying with reliability standard AEC-Q100 and IATF 16969 quality management system, it is also preparing for automotive semiconductor production.
Meanwhile, in cooperation with ecosystem partners, Samsung will host its first SAFETM (Samsung Advanced Foundry Ecosystem) Forum on Oct 17 in San Jose, to introduce Samsung's IP, Electronic Design Automation (EDA), and packaging solutions in detail for foundry partners.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005312/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom